Caitlin Wei-Ming Watson

Caitlin Wei-Ming Watson

Auto-generated profile, based on publicly available information

Caitlin Wei-Ming Watson

Department of Psychiatry, University of California San Diego, San Diego, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Journal of the International Neuropsychological Society
Verified
Journal Article
Closed access
PDF file
CWC. Wei-Ming Watson
C. Wei-Ming Watson
LCLaura M. Campbell
Laura M. Campbell
NSNi Sun-Suslow
Ni Sun-Suslow
SHSuzi Hong
Suzi Hong
AUAnya Umlauf
Anya Umlauf
IGIgor Grant
Igor Grant
Objective: Recent cannabis exposure has been associated with lower rates of neurocognitive impairment in people with HIV (PWH). Cannabis’s anti-inflammatory properties may underlie this relationship by reducing chronic neuroinflammation in PWH. This study examined relations between cannabis use and inflammatory biomarkers in cerebrospinal fluid (CSF) and plasma, and cognitive correlates of these biomarkers within a community-based sample of PWH.Methods: 263 individuals were categorized into four groups: HIV− non-cannabis users (n= 65), HIV+ non-cannabis users (n= 105), HIV+ moderate cannabis users (n= 62), and HIV+ daily cannabis users (n= 31). Differences in pro-inflammatory biomarkers (IL-6, MCP-1/CCL2, IP-10/CXCL10, sCD14, sTNFR-II, TNF-α) by study group were determined by Kruskal–Wallis tests. Multivariable linear regressions examined relationships between biomarkers and seven cognitive domains, adjusting for age, sex/gender, race, education, and current CD4 count.Results: HIV+ daily cannabis users showed lower MCP-1 and IP-10 levels in CSF compared to HIV+ non-cannabis users (p= .015;p= .039) and were similar to HIV− non-cannabis users. Plasma biomarkers showed no differences by cannabis use. Among PWH, lower CSF MCP-1 and lower CSF IP-10 were associated with better learning performance (allps < .05).Conclusions: Current daily cannabis use was associated with lower levels of pro-inflammatory chemokines implicated in HIV pathogenesis and these chemokines were linked to the cognitive domain of learning which is commonly impaired in PWH. Cannabinoid-related reductions of MCP-1 and IP-10, if confirmed, suggest a role for medicinal cannabis in the mitigation of persistent inflammation and cognitive impacts of HIV.

4 January 2022 in Neurology
Verified
Journal Article
Open access
PDF file
MAMilou J. Angevaare
Milou J. Angevaare
JVJet M.J. Vonk
Jet M.J. Vonk
LBLaiss Bertola
Laiss Bertola
LZLaura Zahodne
Laura Zahodne
CWCaitlin Wei-Ming Watson
Caitlin Wei-Ming Watson
JMJennifer J Manly
Jennifer J Manly
Background and Objectives To investigate sociodemographic and medical predictors of incident mild cognitive impairment (MCI) and subsequent course of MCI at follow-up, including sustained MCI diagnosis, classification as cognitively normal, and progression to dementia. Methods Within a community-based cohort, diagnoses of MCI were made with a published algorithm. Diagnosis of dementia was based on clinical consensus. Cox regressions estimated hazard ratios of incident MCI associated with several predictors. Modified Poisson regressions estimated relative risks associated with predictors of diagnostic status at follow-up after incidence. Results Among 2,903 cognitively normal participants at baseline, 752 developed MCI over an average of 6.3 (SD 4.5) years (incidence rate 56 per 1,000 person-years). Presence of APOE ε4 and higher medical burden increased risk of incident MCI, while more years of education, more leisure activities, and higher income decreased this risk. Of the incident MCI cases, after an average of 2.4 years of follow-up, 12.9% progressed to dementia, 9.6% declined in functioning and did not meet the algorithmic criteria for MCI but did not meet the clinical criteria for dementia, 29.6% continued to meet MCI criteria, and 47.9% no longer met MCI criteria. Multidomain MCI, presence of APOE ε4, depressive symptoms, and antidepressant use increased the risk of progression to dementia. Discussion This community-based study showed that almost half of the individuals with incident MCI diagnoses were classified as cognitively normal at follow-up. Predictors of incident MCI demonstrably differed from those of subsequent MCI course; these findings can refine expectations for cognitive and functional course of those presenting with MCI.

1 December 2020 in AIDS Education and Prevention
Verified
Journal Article
Open access
CWC. Wei-Ming Watson
C. Wei-Ming Watson
EPElizabeth Pasipanodya
Elizabeth Pasipanodya
MSMicah J. Savin
Micah J. Savin
EEEric E. Ellorin
Eric E. Ellorin
KCKatya C. Corado
Katya C. Corado
DMDavid J. Moore
David J. Moore
While transgender and gender non-binary (trans/nb) individuals are disproportionately affected by HIV, pre-exposure prophylaxis (PrEP) uptake remains low in this underserved population. We conducted four focus groups with 37 trans/nb individuals in San Diego and Los Angeles to assess barriers and facilitators of PrEP usage. Transcripts were coded for qualitative themes. Although overall PrEP awareness was high, participants reported limited knowledge and misinformation about PrEP. Barriers to PrEP use included: structural access (e.g., discrimination from health care providers, lack of trans-inclusive services, financial barriers), mental health struggles limiting ability to access PrEP, and concerns about potential side effects, drug-drug interactions with hormone therapy, and lack of other STI protection. Facilitators of PrEP usage included: increased PrEP availability, prior experience taking daily medications, and motivation to have active and healthy lives without fear of contracting HIV. Addressing both structural and psychosocial/behavioral factors in trans-affirming health care environments is crucial to designing inclusive, effective PrEP interventions.

8 May 2023 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
CWCaitlin Wei-Ming Watson
Caitlin Wei-Ming Watson
ESErin Sundermann
Erin Sundermann
JHJonathan Helm
Jonathan Helm
EPEmily W. Paolillo
Emily W. Paolillo
SHSuzi Hong
Suzi Hong
Igor GrantIgor Grant
Igor Grant

9 May 2019
Verified
Reference Entry
Closed access
JIJennifer Elizabeth Iudicello
Jennifer Elizabeth Iudicello
EMErin E. Morgan
Erin E. Morgan
MHMariam A. Hussain
Mariam A. Hussain
CWCaitlin Wei-Ming Watson
Caitlin Wei-Ming Watson
RHRobert K. Heaton
Robert K. Heaton
Human immunodeficiency virus enters the central nervous system (CNS) early after systemic infection, and may cause neural injury and associated neurocognitive impairment through multiple direct and indirect mechanisms. An international conference of multidisciplinary neuroAIDS experts convened in 2005 to propose operationalized research criteria for HIV-related cognitive and everyday functioning impairments. The resulting classification system, known as the Frascati criteria, defined three types of HIV-associated neurocognitive disorder (HAND): asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia (HAD). Consideration of comorbid conditions that can influence neurocognitive performance, such as developmental disabilities, non-HIV forms of CNS compromise (neurological and systemic), severe psychiatric conditions, and substance use disorders, is essential to differential diagnosis. Since the introduction of combination antiretroviral therapy (ART), rates of severe HAND (i.e., HAD) have greatly declined, although the milder forms of HAND remain quite prevalent, even in virally suppressed people living with HIV (PLWH). Beyond ART, clinical management of HAND includes behavioral interventions focused on neurocognitive and functional improvements. This chapter covers a range of HAND-related topics, such as the neuropathological mechanisms of HIV-related CNS injury, assessment and diagnostic systems for neurocognitive and everyday functioning impairment in HIV, treatment and protective factors, aging with HIV, HAND in international settings, and ongoing challenges and controversies in the field. Future needs for progress with HAND include advances in early detection of mild cognitive deficits and associated functional impairment in PLWH; biomarkers that may be sensitive to its underlying pathogenesis; and differential diagnosis of HAND versus age-related, non-HIV-associated disorders.